# Study of MLN8237 in Participants With Advanced Hematological Malignancies

> **NCT00697346** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 58 (actual)

## Conditions studied

- B-cell Follicular Lymphoma
- B-cell Marginal Zone Lymphoma
- Diffuse Large B-cell Lymphoma
- B-cell Mantle Cell Lymphoma
- B-cell Small Lymphocytic Lymphoma
- B-Cell Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Waldenstrom's Macroglobulinemia
- Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Enteropathy Associated T-cell Lymphoma
- NK Lymphoma

## Interventions

- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT00697346
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-11
- **Primary completion:** 2016-10-01
- **Final completion:** 2016-10-19
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2019-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697346, "Study of MLN8237 in Participants With Advanced Hematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00697346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*